Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin

Part of paid clinical trials in San Antonio, Texas.

Sponsor
The University of Texas Health Science Center at San Antonio
Study ID
NCT02984644
Phase
PHASE3
Status
Completed

Conditions

  • Type II; Diabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
  • Placebo — DRUG
    Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.

Study Details

To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.

Key Dates

Start date
Sep 6, 2017
Status verified
Nov 2019
Primary completion
Nov 16, 2018
Completion
Nov 16, 2019

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Dapagliflozin
    32 subjects will receive dapagliflozin 10mg
  • Placebo Comparator: Placebo
    16 subjects will receive placebo

Primary Outcome Measure

Measurement of the Change in Plasma Glucose (mg/dL): Study 1 [ Time Frame: Baseline to 240-300 minutes ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Health Science CenterSan AntonioTexas78229-

Find similar trials in San Antonio, TX

By research site
University of Texas Health Science Center· San Antonio, TX